Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,663 across all filing types
Latest filing 2025-08-14 Major Shareholding Noti…
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-13 English
8-K
Regulatory Filings
2025-08-12 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-11 English
Quarterly Results Announcement and SEC Form 10-Q 42 pages 989.6KB
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q Quarterly Report for the quarter ended June 30, 2025, filed with the U.S. Securities and Exchange Commission (SEC). It includes condensed consolidated financial statements prepared according to US GAAP, management discussion and analysis, risk factors, and other required disclosures typical of a quarterly report. The text explicitly references the Form 10-Q and contains detailed financial data and analysis for the quarter, which matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the correct classification is IR with high confidence.
2025-08-11 English
Results for the Second Quarter of 2025 3 pages 285.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Anteris Announces Results for the Second Quarter of 2025' and provides detailed financial results for the quarter ended June 30, 2025, including operating cash outflows, R&D expenses, and selling, general and administrative expenses. It also includes operational updates, clinical trial progress, and corporate board appointments. The presence of detailed financial data for a quarter and the date range indicate this is a quarterly financial report. The document references the Form 10-Q filing for more detailed financial information, which is consistent with an Interim / Quarterly Report. The document length is over 10,000 characters and contains substantive financial data and analysis, not just an announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-08-11 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.